Hyderabad-based Vivimed Labs has acquired Uquifa, manufacturer of active pharma ingredients (APIs) and intermediates with operations in Spain and Mexico, for a consideration of $ 55 million. In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, the company has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico. The investment consideration of $ 55 million is paid by equity infusion of $ 20 million, debt financing of $ 25 million and the balance of $ 10 million by way of deferred payment. Uquifa will become the active pharmaceutical ingredient (API) division of the Vivimed group.
The acquisition would strengthen the company's current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa. Uquifa sells in over 70 countries and has over 150 active DMFs filed and 20 COS approved. The company has a net assets of $ 65 million and gross assets of $ 100 million as of this June.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.50 |
| Dr. Reddys Lab | 1220.50 |
| Cipla | 1232.75 |
| Zydus Lifesciences | 927.80 |
| Lupin | 2321.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: